ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR)
Phase 4
Completed
- Conditions
- Overactive BladderUrinary IncontinenceUrge Incontinence
- Interventions
- Behavioral: Simplified bladder trainingDrug: Solifenacin succinate
- First Posted Date
- 2006-06-16
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 643
- Registration Number
- NCT00337558
A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)
Phase 2
Completed
- Conditions
- Overactive Bladder
- First Posted Date
- 2006-06-15
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 1108
- Registration Number
- NCT00337090
- Locations
- 🇷🇺
3 Sites, St Petersburg, Russian Federation
🇸🇪2 Sites, Stockholm, Sweden
🇷🇺7 Sites, Moscow, Russian Federation
A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.
Phase 4
Completed
- Conditions
- Urinary Incontinence
- Interventions
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 398
- Registration Number
- NCT00333112
LUCY: A Study for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in Patients Previously Treated With Chemotherapy
Phase 2
Completed
- Conditions
- Lung CancerCancer of LungCancer of the LungNon-Small Cell Lung CarcinomaCarcinoma, Non-Small Cell Lung
- Interventions
- First Posted Date
- 2006-05-22
- Last Posted Date
- 2008-01-02
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 37
- Registration Number
- NCT00328588
Comparison of Two Tacrolimus Based Immunosuppressive Regimens in Recipients Receiving Marginal Donor Kidneys
Phase 3
Completed
- Conditions
- KIDNEY TRANSPLANTATION
- Interventions
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 142
- Registration Number
- NCT00321113
Tacrolimus and Daclizumab Versus Tacrolimus and Steroids in Liver Recipients Receiving Sub-optimal Grafts
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2014-08-26
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 101
- Registration Number
- NCT00321074
A Double Blind Placebo Controlled Study to Assess the Efficacy on Joint Damage in RA Patients
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2014-08-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 123
- Registration Number
- NCT00319917
An Open Study for Steroid Resistant, Non-Thymectomized MG Patients
- First Posted Date
- 2006-03-31
- Last Posted Date
- 2009-06-03
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 11
- Registration Number
- NCT00309101
FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients
- First Posted Date
- 2006-03-31
- Last Posted Date
- 2014-08-25
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 80
- Registration Number
- NCT00309088
Optimizing Prograf® Therapy in Renal Transplant Patients
Phase 4
Completed
- Conditions
- Renal Transplantation
- First Posted Date
- 2006-03-01
- Last Posted Date
- 2008-08-26
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 323
- Registration Number
- NCT00297765
© Copyright 2025. All Rights Reserved by MedPath